Promising cancer combo trial ends early after just 10 patients
NCT ID NCT06337630
First seen Jan 06, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This early-phase study tested two experimental drugs, tuvusertib and PLX038, in people with advanced solid tumors that could not be cured. The goal was to find the safest dose and see if the combination could shrink tumors. Only 10 people took part before the trial was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie
Paris, 75005, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.